INDOLIN-2-ONE UND AZA-INDOLIN-2-ONE

European patent · EP2170827 · In force

Register entry

Publication number
EP2170827
Application number
EP08774198
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 20, 2008
Published
Apr 7, 2010
Granted
Aug 14, 2013
Protection ends at the latest
Jun 19, 2028
Next annual fee due
Jun 30, 2027
IPC classes
C07D 209/34 (2006.01)
C07D 471/04 (2006.01)
C07D 487/04 (2006.01)
A61K 31/404 (2006.01)
A61K 31/407 (2006.01)
A61P 35/00 (2006.01)
Priority
EP 07110764 21.06.2007
PCT application
PCT/EP2008/057909 20.06.2008
PCT publication
WO2008/155421 24.12.2008
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  6. Aug 14, 2013

    Granted

    Published in Swissreg on 14.08.2013

Parties

Holder

Janssen Pharmaceutica N.V.

Janssen Pharmaceutica, N.V.

Turnhoutseweg 30, 2340 Beerse, BE

Inventor

DIELS, Gaston, Stanislas, Marcella

B-2340 Beerse, BE

VERDONCK, Marc, Gustaaf, Celine

B-2275 Gierle, BE

BUIJNSTERS, Peter, Jacobus, Johannes, Antonius

B-2340 Beerse, BE

VAN EMELEN, Kristof

B-2340 Beerse, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.